医院获得性/呼吸机相关性细菌性肺炎临床试验抗菌疗效共识终点
VABP终点依次为28天生存、28天内无机械通气天数、第7-10天临床治愈;HABP终点为28天生存和第7-10天临床治愈。超过70%专家同意上述评估时间点,终点层级经3轮德尔菲达成72%共识。
要点
- VABP采用分层复合终点:28天生存优先,其次28天内无机械通气天数,再次第7-10天临床治愈。
- HABP采用分层复合终点:28天生存优先,其次第7-10天临床治愈。
- 临床治愈定义为入组时症状体征消退且影像学改善或未进展。
核心结论
- 国际专家共识推荐VABP和HABP分别采用不同的分层复合终点,并给出临床治愈定义,供未来HABP/VABP抗菌药物临床试验使用。
主要发现
- 超过70%专家同意评估28天生存、28天内无机械通气天数以及治疗开始后第7-10天临床治愈。
- 终点组分的层级顺序经3轮德尔菲后达到72% agreement。
关键数值与推荐
- VABP复合终点按优先级依次为:28天生存、28天内无机械通气天数、第7-10天临床治愈。
- HABP复合终点按优先级依次为:28天生存、第7-10天临床治愈。
- 临床治愈定义为入组时存在的症状体征消退,同时影像学征象改善或未进展。
临床怎么用
- 设计HABP/VABP抗菌药物临床试验时,可采用该共识推荐的分层复合终点和临床治愈定义,以减少终点异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP. METHODS: Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method. RESULTS: The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation-free days through day 28, and (3) clinical cure between study days 7 and 10 for VABP; and (1) survival (day 28) and (2) clinical cure (days 7-10) for HABP. Clinical cure was defined as the combination of resolution of signs and symptoms present at enrollment and improvement or lack of progression of radiological signs. More than 70% of the experts agreed to assess survival and mechanical ventilation-free days though day 28, and clinical cure between day 7 and day 10 after treatment initiation. Finally, the hierarchical order of endpoint components was reached after 3 Delphi rounds (72% agreement). CONCLUSIONS: We provide a multinational expert consensus on separate hierarchical composite endpoints for VABP and HABP, and on a definition of clinical cure that could be considered for use in future HABP/VABP clinical trials.
引用
- Weiss E, Zahar JR, Alder J, et al. Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clin Infect Dis. 2019. PMID: 30722013. doi:10.1093/cid/ciz093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。